On November 5, 2025, Bliss GVS Pharma Limited announced the allotment of 33,670 equity shares under its Employee Stock Option Plan (ESOP) 2019. This decision was made during a meeting of the ESOP Allotment Committee and marks an important step in the company's strategy to incentivize its employees. The shares have a face value of Re. 1 each and were issued to eligible employees who exercised their stock options. This allotment is part of the company's ongoing commitment to reward its workforce and align their interests with those of the company.

As a result of this allotment, Bliss GVS Pharma's issued, subscribed, and paid-up share capital has risen from Rs. 10,56,88,923 to Rs. 10,57,22,592. The total number of equity shares has increased from 10,56,88,923 to 10,57,22,592. This increase reflects not only the company's growth but also its adherence to the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, which governs the issuance of shares through employee stock options. The details of the allotment have been duly filed with the BSE and NSE, ensuring regulatory compliance.

The newly allotted shares will be subject to a lock-in period of six months, expiring on May 5, 2026. This means that the employees who have received these shares must hold them for this duration before they can sell or transfer them. Importantly, all new shares will rank pari passu with existing shares, indicating they will have the same rights and privileges as current equity holders. This strategic move by Bliss GVS Pharma reinforces its focus on employee engagement and long-term growth in line with market opportunities.